Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0285 • ACR Convergence 2020
CXCL13 Neutralization Reduces Neuropsychiatric Manifestations in MRL/lpr Mice
Michelle Huang¹, Ariel Stock¹ and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Targeted treatments for neuropsychiatric systemic lupus erythematosus (NPSLE) remain challenging to develop due to the unclear pathogenesis of the disease. Our laboratory has previously…
Abstract Number: 0302 • ACR Convergence 2020
Longitudinal Study of Acute SLE Flare Reveals Dynamic Changes in Multiple Immune Cell Subsets
Kieran Manion¹, Dennisse Bonilla², Dafna Gladman¹, Murray Urowitz³, Zahi Touma⁴ and Joan Wither², ¹Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: In SLE, periods of relative quiescence are punctuated by flares in disease activity that can lead to extensive tissue damage and morbidity. Existing studies…
Abstract Number: 0498 • ACR Convergence 2020
Exploring the Role of Lipocalin-2 in Neuropsychiatric SLE Pathogenesis
Chaim Putterman¹, Elise Mike¹ and Sayra Garcia¹, ¹Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: While the etiology of neuropsychiatric lupus (NPSLE) is not fully understood, blood brain barrier (BBB) disruption and localized neuroinflammation are potential mechanisms that contribute…
Abstract Number: 0618 • ACR Convergence 2020
The Effect of Travel Burden on Depression and Anxiety in African American Women Living with Systemic Lupus
Trevor Faith¹, Ashley White¹, Aissatou Ba¹, Viswanathan Ramakrishnan², Hetlena Johnson³, Jillian Rose⁴, Clara Dismuke-Greer⁵, Jim Oates⁶, Leonard Egede⁷ and Edith Williams¹, ¹Medical University of South Carolina, Charleston, SC, ²medical university of south carolina, south carolina, ³LupusCSC, Columbia, SC, ⁴Hospital for Special Surgery, New York, ⁵Palo Alto VA, Palo Alto, CA, ⁶Medical University of South Carolina, Charleston, SC, Charleston, SC, ⁷Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: The United States has a deficit of rheumatology specialists. This leads to an increased burden accessing care for patients with autoimmune and connective tissue…
Abstract Number: 0852 • ACR Convergence 2020
How Much Prednisone Is Enough for Remission Induction in Lupus Nephritis? A Propensity Score Matched Analysis
Konstantinos Tselios¹, Dafna Gladman², Haifa Al-Sheikh³, Jiandong Su⁴ and Murray Urowitz¹, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³King Faisal Specialist Hospital and Research Centre, Riyadh, Ar Riyad, Saudi Arabia, ⁴University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada
Background/Purpose: The existing guidelines for remission induction in lupus nephritis (LN) from both the ACR and the EULAR recommend initial prednisone doses of 0.5-1mg/kg/day. However,…
Abstract Number: 0870 • ACR Convergence 2020
Hydroxychloroquine Is Associated with Lower Platelet Activity and Improved Vascular Health in Systemic Lupus Erythematosus
Michael Golpanian¹, Elliot Luttrell-Williams², MacIntosh Cornwell², Khrystyna Myndzar², Hanane El Bannoudi², Ashira Blazer², Stuart Katz², Nathaniel Smilowitz², Kelly Ruggles², Robert Clancy³, Jill Buyon⁴ and Jeffrey Berger², ¹New York University, New York, NY, ²New York University School of Medicine, New York, ³NYU School of Medicine, New York, ⁴Department of Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk of premature atherosclerosis and thrombosis. Hydroxychloroquine (HCQ) is widely used in the treatment of…
Abstract Number: 0986 • ACR Convergence 2020
BIIB059, a Humanized Monoclonal Antibody Targeting Blood Dendritic Cell Antigen 2 on Plasmacytoid Dendritic Cells, Shows Dose-Related Efficacy in a Phase 2 Study in Participants with Active Cutaneous Lupus Erythematosus
Victoria Werth¹, Richard Furie², Juanita Romero-Díaz³, Sandra Navarra⁴, Kenneth Kalunian⁵, Ronald van Vollenhoven⁶, Filippa Nyberg⁷, Benjamin Kaffenberger⁸, Saira Sheikh⁹, Goran Radunovic¹⁰, Xiaobi Huang¹¹, Hua Carroll¹², Francois Gaudreault¹², Adam Meyers¹¹, Catherine Barbey¹³, Cristina Musselli¹¹ and Nathalie Franchimont¹¹, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁴University of Santo Tomas, Manila, Philippines, ⁵University of California San Diego, La Jolla, CA, ⁶Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁷Karolinska University Hospital, Stockholm, Sweden, ⁸Ohio State University, Columbus, OH, ⁹Division of Rheumatology, Allergy and Immunology, University of North Carolina, Chapel Hill, NC, ¹⁰Institute of Rheumatology, University of Belgrade, Belgrade, Serbia, ¹¹Biogen, Cambridge, MA, ¹²Biogen, Cambridge, ¹³Biogen, Baar, Switzerland
Background/Purpose: No approved targeted therapies have been developed for cutaneous lupus erythematosus (CLE), a disfiguring autoimmune disease that severely impairs quality of life.1 BIIB059 is…
Abstract Number: 1131 • ACR Convergence 2020
Patient Perspective of Helpfulness of Lupus Medications: A Qualitative Study of Medication Use Within the Type 1 and 2 SLE Model
Mithu Maheswaranathan¹, Kevin McKenna², Amy Corneli², David Pisetsky³, Megan Clowse⁴ and Amanda Eudy¹, ¹Duke University, Durham, NC, ²Duke University, Durham, ³Duke University Medical Center, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: Medication management in systemic lupus erythematosus (SLE) is particularly complex given the clinical heterogeneity of symptoms and a wide range of medications used. We…
Abstract Number: 1267 • ACR Convergence 2020
Perceived Stress During the COVID-19 Pandemic Independently Associates with Worse Patient-Reported Outcomes in Systemic Lupus Erythematosus (SLE)
Sarah Patterson¹, Laura Trupin², Kimberly DeQuattro¹, Cristina Lanata¹, Maria Dall'Era³, Jinoos Yazdany² and Patricia Katz², ¹UCSF, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³Division of Rheumatology, University of California, San Francisco, CA
Background/Purpose: Causes and risk factors for variations in SLE disease activity and symptom severity are incompletely understood. Prior studies suggest a link between stressful life…
Abstract Number: 1283 • ACR Convergence 2020
Factors Affecting Mortality of Systemic Lupus Erythematosus Patients in Spain in the 21st Century: Data from the RELESSER Registry
Clara Moriano¹, Jaime Calvo-Alén², Iñigo Rúa-Figueroa³, Elvira Díez Álvarez¹, Cristina Bermúdez⁴, Francisco J López-Longo⁵, Maria Galindo-Izquierdo⁶, Alejandro Olivé-Marqués⁷, Eva Tomero Muriel⁸, Antonio Fernandez-Nebro⁹, Mercedes Freire-González¹⁰, Olaia Fernandez-Berrizbeitia¹¹, Ana Pérez Gómez¹², Maria Esther Uriarte¹³, Carlos Marras Fernández-Cid¹⁴, Carlos Montilla Morales¹⁵, Gregorio Santos Soler¹⁶, Ricardo Blanco¹⁷, Manuel Rodríguez-Gómez¹⁸, Paloma Vela¹⁹, Alina Lucica Boteanu²⁰, Francisco Javier Narváez²¹, Victor Martinez Taboada²², Blanca Hernández Cruz²³, Jose Luis Andreu Sanchez²⁴, Jose A Hernández-Beriain²⁵, Lorena Expósito²⁶, Raul Menor Almagro²⁷, Mónica Ibañez-Barceló²⁸, Ivan Castellvi²⁹, Carlos Galisteo³⁰, Enrique Raya³¹, VE Quevedo-Vila³², Tomás Vázquez³³, J Ibáñez-Ruan³⁴ and Jose Maria Pego-Reigosa³⁵, ¹Complejo Asistencial Universitario de León, León, Spain, ²Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ³Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain, ⁴Research Unit Bioaraba, Vitoria, Spain, ⁵Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Hospital Germans Trias i Pujol, Barcelona, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Madrid, Spain, ⁹University of Malaga, Malaga, Spain, ¹⁰CHU Coruña, Coruña, Spain, ¹¹Basurto University Hospital, Bilbao, Spain, ¹²Hospital Universitario Príncipe Asturias, Alcalá de Henares, Madrid, Spain, ¹³Hospital Universitario Donostia, San Sebastian, Spain, ¹⁴Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ¹⁵Hospital Universitario de Salamanca, Salamanca, Spain, ¹⁶Hospital Marina Baixa, Alicante, Spain, ¹⁷Hospital Universitario Marques de Valdecilla, Santander, Spain, ¹⁸Hospital Complex of Ourense, Ourense, Spain, ¹⁹Hospital General Alicante, Alicante, Spain, ²⁰PRINTO, Istituto Giannina Gaslini, Genova, Italy, ²¹Hospital Bellvitge, BARCELONA, Spain, ²²Marqués de Valdecilla University Hospital, Santander, Spain, ²³Universidad de Sevilla, Sevilla, Spain, ²⁴Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ²⁵Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ²⁶Hospital Clinico Tenerife, Tenerife, Spain, ²⁷Hospital General Universitario de Jerez de la Frontera, Puerto De Santa Mar�a, Spain, ²⁸Hospital Son Llatzer, Mallorca, Spain, ²⁹Hospital Santa Creu i Sant Pau, Barcelona, Spain, ³⁰Hospital Parc Taulí, Barcelona, Spain, ³¹Hospital San Cecilio, Granada, Spain, ³²Hospital Comarcal de Monforte, Lugo, Spain, ³³Hospital Lucus Augusti, Lugo, Spain, ³⁴Hospital Povisa, Vigo, Pontevedra, Spain, ³⁵University Hospital of Vigo, Galicia Sur Health Research Institute, Vigo, Spain
Background/Purpose: The mortality in Systemic Lupus Erythematosus (SLE) varies largely across different countries most probably due to social, healthcare and ethnic differences.To analyze the causes…
Abstract Number: 1299 • ACR Convergence 2020
Longitudinal Patterns of Anxiety Symptomology Among Patients with Systemic Lupus Erythematosus (SLE) Remain Stable over Time and Do Not Associate with SLE Disease Activity
Daphne Lew¹, Xinliang Huang², Sara Kellahan², Hong Xian³, Seth Eisen⁴ and Alfred Kim⁵, ¹Washington University in St. Louis School of Medicine, Saint Louis, MO, ²Division of Rheumatology, Washington University in St. Louis School of Medicine, St. Louis, ³Department of Epidemiology and Biostatistics, College for Public Health and Social Justice, Saint Louis University, St. Louis, ⁴Washington University School of Medicine, St Louis, MO, ⁵Washington University School of Medicine, St. Louis, MO
Background/Purpose: Almost 40% of patients with SLE have comorbid mental health conditions.1 Though depression is most commonly reported (24% to 30%), many SLE patients also…
Abstract Number: 1509 • ACR Convergence 2020
Leukocyte Telomere Length and Childhood Onset of Systemic Lupus Erythematosus in the Black Women’s Experiences Living with Lupus (BeWELL) Study
John Bridges¹, Kara Chung², Connor Martz², Emily Smitherman¹, Cristina Drenkard³, S. Sam Lim⁴ and David Chae², ¹University of Alabama at Birmingham, Birmingham, AL, ²Auburn University, Auburn, AL, ³Division of Rheumatology, Department of Medicine, Emory School of Medicine, Atlanta, GA, ⁴Emory University, Atlanta, GA
Background/Purpose: Childhood-onset SLE is generally more aggressive than adult-onset SLE. Leukocyte telomere length (LTL) has been posited to reflect immune system aging. Short LTL in…
Abstract Number: 1666 • ACR Convergence 2020
Elucidating Research Priorities in Childhood-Onset Systemic Lupus Erythematosus: A Qualitative Study
Laura Cannon¹, Anne Skelley-Caliendo², Aimee Hersh³ and Andrea Knight⁴, ¹Duke University, Durham, NC, ²Northwestern University, Chicago, IL, ³University of Utah and Primary Children's Hospital, Salt Lake City, ⁴Division of Rheumatology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: An estimated 15 to 20% of patients with systemic lupus erythematosus (SLE) have childhood-onset SLE (cSLE). Given the early onset of cSLE, patients often…
Abstract Number: 1766 • ACR Convergence 2020
Trends of Pregnancy Outcomes in a Large Electronic Health Record Cohort of Systemic Lupus Erythematosus Patients
April Barnado¹, Alex Camai¹ and Lee Wheless¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Studying pregnancy in systemic lupus erythematosus (SLE) is difficult given its relative rarity. Electronic health record (EHR) contain longitudinal data to serve as a…
Abstract Number: 1797 • ACR Convergence 2020
A Multianalyte Assay Panel (MAP) with Algorithm Containing Cell-Bound Complement Activation Products (CB-CAPs) Is Superior to Anti-dsDNA and Low Serum Complement Levels in Predicting Transition of Probable Lupus to ACR Classified Lupus Within 2 Years
Rosalind Ramsey-Goldman¹, Roberta Vezza Alexander², Cristina Arriens³, Sonali Narain⁴, Elena Massarotti⁵, Daniel J Wallace⁶, Amit Saxena⁷, Christopher Collins⁸, Chaim Putterman⁹, Kenneth Kalunian¹⁰, Armida Sace², Rowena LaFon², JoAnne Ligayon², John Conklin¹¹ and Arthur Weinstein¹², ¹Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Exagen Inc, Vista, CA, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Northwell Health, Great Neck, NY, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Cedars-Sinai Medical Center, Beverly Hills, CA, ⁷NYU School of Medicine, New York, ⁸MedStar Washington Hospital Center, Washington, DC, ⁹Albert Einstein College of Medicine, Bronx, NY, ¹⁰University of California San Diego, La Jolla, CA, ¹¹Exagen Inc., Vista, CA, ¹²Loma Linda University and Exagen, Inc, Claremont, CA
Background/Purpose: We reported previously (Ramsey-Goldman et al., Arthritis Rheumatol 2020) that score > 0.8 of a multianalyte assay panel (MAP) with algorithm predicts fulfillment of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].